key: cord-0866105-rjgxx0gq
authors: Franchini, Massimo; Liumbruno, Giancarlo Maria; Pezzo, Mario
title: COVID‐19 vaccine‐associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome
date: 2021-06-09
journal: Eur J Haematol
DOI: 10.1111/ejh.13665
sha: 10046b2d707b09da0ef378074571b9bedd5c1bf3
doc_id: 866105
cord_uid: rjgxx0gq

Very rare cases of thrombosis associated with thrombocytopenia have occurred following the vaccination with AstraZeneca COVID‐19 vaccine. The aim of this concise review is to summarize the current knowledge on the epidemiologic and pathogenic mechanisms of this syndrome named vaccine‐associated immune thrombosis and thrombocytopenia (VITT). A practical patient management section will also be dealt with using information available from national and international scientific societies as well as expert panels. A literature search on the VITT syndrome was carried out in PubMed using appropriate MeSH headings. Overall, 40 VITT cases have been reported. Continuous pharmacovigilance monitoring is needed to collect more data on the real incidence and the pathogenesis of VITT syndrome. Such information will also help us to optimize the management this rare but often clinically severe thrombotic condition associated with COVID‐19 vaccination.

Health Organization (WHO). 2 More than a year after the pandemic outbreak, very few therapeutic weapons have been shown to be able to fight COVID-19, the most relevant including steroids and antibody-based therapies. [3] [4] [5] The main progress of pharmaceutical research has been undoubtedly the development of vaccines, available in Europe only 9 months after the first case of SARS-CoV-2 infection. 6 Currently, four COVID-19 vaccines have Vaccine Janssen by Janssen-Cilag International NV). 7 Considering the public health emergency, EMA accelerated the procedures for COVID-19 vaccine evaluation, releasing a conditional marketing authorization and guaranteeing at the same time a continuous and rigorous safety monitoring through the European pharmacovigilance system. 8 While the post-authorization surveillance performed by national and international health authorities did not show particular safety concerns following the administration of more than 700 million of COVID-19 vaccine doses worldwide, very rare cases of thrombosis at unusual sites, mostly cerebral or sinus vein thrombosis (CVT), associated with thrombocytopenia have been reported shortly after the administration of the AstraZeneca (ChAdOx1 nCov-19) COVID-19 vaccine. 9 This paper summarizes the current knowledge on this rare but severe condition, named Vaccine-associated Immune Thrombosis and Thrombocytopenia (VITT) syndrome, focusing in particular on epidemiologic, pathogenic, clinical, diagnostic, and therapeutic issues.

As a search literature strategy, the Medline and PubMed electronic database was searched for publications on VITT syndrome between November 2020 and April 2021 using English language as a restriction. The Medical Subject Heading (MeSH) and key words used were: "COVID-19 vaccine," "AstraZeneca," "Vaxzevria," "ChAdOx1 nCoV-19 vaccine," "SARS-CoV-2," "coronavirus," "thrombosis," "cerebral sinus vein thrombosis," "unusual sites," "pulmonary embolism," "immune thrombocytopenia," "heparin-induced thrombocytopenia," "thrombotic thrombocytopenia," "adverse reaction." We also screened the reference lists of the most relevant review articles and other publications for additional studies not captured in our initial literature search.

The incidence of VITT appears to be between 1 in 125 000 and 1 in 1 million of vaccinated cases. 10 14 Although EMA, in a statement dated April 7th, 2021, suggested a possible link between unusual blood clots with low blood platelets and AstraZeneca COVID-19 vaccine, it concluded that the overall benefits far outweigh the risks of side effects. 9 Nevertheless, PRAC continued to monitor AstraZeneca COVID-19 vaccine safety and effectiveness as for all other vaccines. 9 Although EMA did not restrict the use of AstraZeneca COVID-19 vaccine to particular categories of subjects, many European and non-European countries made decisions on their own: the Danish Health and Medicine authority decided to temporarily (3 weeks) suspend AstraZeneca vaccine, The Netherlands and Germany administered the vaccine only to subjects over 60 years of age, France and Canada only to over 55 years of age and Sweden and Finland only to over 65 years of age. The Italian AIFA left the prescription of the AstraZeneca vaccine free suggesting, however, a preferential use over the age of 60. In any case, the situation is constantly evolving, depending on the number of VITT cases reported in relation to the number of vaccinations, and it is likely that at the time of publication it has changed again.

While thrombotic events in VITT are preferentially, but not exclusively, located in intracranial veins, the concomitant thrombocytopenia suggests an immunological cause of the hypercoagulative tendency. 15 The pathogenic mechanism, which has been recently clarified by the German Greifswald Working Group under the leadership of Andreas Greinacher, resembles that of heparin-induced thrombocytopenia (HIT), 10 a prothrombotic disorder provoked by IgG-specific antibodies that recognize multimolecular complexes between the cationic platelet-factor 4 (PF4) and the anionic heparin and cause platelet activation through the FcγRIIA receptor. 16, 17 However, the fact which renders unique this condition is that it occurs in COVID-19-vaccinated patients who did not receive any heparin treatment during their life. Thus, an anionic substance other than heparin must be involved to explain the genesis of this prothrombotic syndrome which has been called 'spontaneous' or autoimmune HIT. 15, 17, 18 It has been, indeed, recently recognized that triggers other than heparin can cause a prothrombotic disorder with clinical and laboratory features that strongly resemble HIT. These include certain highly sulfated and highly negatively charged oligosaccharides, such as pentosan polysulfate, hypersulfated chondroitin sulfate and related molecules. [19] [20] [21] In addition to exposure to polyanionic medications, a HIT-like phenomenon has also been observed after knee-replacement surgery and bacterial or viral and infections. [21] [22] [23] [24] These latter findings are in agreement with the antimicrobial, beyond procoagulant, suggested activity of PF4. 25, 26 In response to microorganisms, indeed, activated platelets release PF4 contributes to the recruitment of neutrophils and facilitates neutrophil exocytosis to release myeloperoxidase and lysozyme. 27 In addition, PF4 binds directly to bacteria thus creating a neoantigen which is targeted by anti-PF4/heparin or anti-PF4/ polyanion antibodies to form immune complexes that play a key role in antibacterial host defense. 26 A similar mechanism could also be implicated in the antiviral response to SARS-CoV-2 infection, considering that non-platelet-activating and platelet-activating anti-PF4/heparin antibodies have been detected by several investigators in COVID-19 patients. [28] [29] [30] Regarding the cases of VITT syndrome observed after AstraZeneca COVID-19 vaccine administration, anti-PF4 antibodies might be elicited by the inflammatory stimulus of the vaccination or by the vaccine itself, which cross-reacts with PF4 and platelets.

With this regards, Greinacher and colleagues found an enhanced reactivity of VITT patients' serum with platelets in the presence of AstraZeneca COVID-19 vaccine, 11 suggesting that interactions between the vaccine and platelets or between the vaccine and PF4 could play a role in pathogenesis. The adenovirus used as a vector in AstraZeneca vaccine could be involved in this pathway: It is well known, indeed, that adenovirus has a strong affinity for PF4 and can cause platelet activation. 31, 32 Finally, different polymorphisms in exon 4 of the FcγRIIA region could be implicated in the modulation of the immune-complexdependent thrombotic risk in VITT patients. 33 Further experimental studies are required to elucidate the exact mechanism through which AstraZeneca COVID-19 vaccine triggers the generation of anti-PF4 autoantibodies.

The onset of moderate to severe thrombocytopenia and thrombotic complications at unusual sites, particularly CVT, beginning approximately 1-2 weeks after vaccination against SARS-CoV-2 with AstraZeneca is strongly suggestive for VITT. 15 To date, 40 cases of VITT have been published [34] [35] [36] [37] and their main characteristics are summarized in Table 1 Regarding the laboratory aspects, apart from thrombocytopenia, the diagnostic hallmark is the positivity of the HIT enzyme-linked immunosorbent assay (ELISA), which identifies antibodies to PF4 and needs to be confirmed by a functional heparin-induced platelet activation assay (HIPA) or serotonin-release assay (SRA). 15 The current available data demonstrate that ELISA HIT assays have the most appropriate sensitivity for all pathophysiologically relevant anti-PF4 antibodies. Other HIT assay methods have shown a low sensitivity. 15 Ninety-five percent (36/38) of valuable VITT cases reported so far resulted positive for ELISA HIT assay (Table 1 ). Figure 1 reports the diagnostic algorithm of VITT syndrome.

Summarizing the data reported in Table 1 , it can be assumed that VITT is a very severe condition, which arises most frequently in young female individuals 1-2 weeks after the first dose of AstraZeneca COVID-19 vaccine and is almost invariably characterized by severe thrombocytopenia and CVT with a fatality rate higher than 60%. 

The VITT syndrome is a very rare but often life-threatening thrombotic condition associated with ChAdOx1 nCoV-19 vaccine. On the basis of the few cases reported, it seems that young females, particularly those under hormonal contraception, are those at highest risk of developing this vaccine-related adverse reaction. However, this finding could be an artifact due to the fact that this vaccine was registered until recently only for individuals under 55 years of age and that a consistent proportion of women take anti-conception pill during childbearing age. The situation is, however, rapidly changing with daily updates from national and international health authorities.

The current therapeutic management of confirmed VITT is based on treatment with IVIG and non-heparin anticoagulants. Further surveillance safety data in parallel with clinical and experimental studies are needed to definitely assess the incidence of VITT, its pathogenesis, and optimal management. Additional research is also required to identify, if possible, those individuals at increased risk of developing VITT syndrome in order to prevent this fearsome complication.

The authors declare no conflicts of interest.

MF involved in study conception and design. All authors are involved in data analysis, interpretation, and manuscript writing, editing, and approval.

Not applicable. 

World Health Organization (WHO)

Convalescent plasma for the treatment of severe COVID-19

Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis

Trial investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies

Treatment and vaccines for COVID-19

Conditional marketing authorization

AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

Vaccine-induced prothrombotic immune thrombocytopenia VIPIT following AstraZeneca COVID-19 vaccination: interim guidance for healthcare professionals in emergency department and inpatient settings

GTH. Updated GTH statement on vaccination with AstraZeneca COVID-19 vaccine, as of

Medicines and Healthcare products Regulatory Agency (MHRA)

Eudravigilance -European database of suspected adverse reaction reports

Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH

Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET)

Heparin-induced thrombocytopenia

Autoimmune heparininduced thrombocytopenia

Pentosan polysulfateinduced thrombocytopenia and thrombosis

Treatment with the novel anti-angiogenic agent PI-88 is associated with immunemediated thrombocytopenia

Pentosan-induced thrombocytopenia: support for an immune complex mechanism

Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT?

Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty

A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia

Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin induced thrombocytopenia

Platelet factor 4 binding to lipid A of Gram negative bacteria exposes PF4/heparin-like epitopes

Structural features and PF4 functions that occur in heparin-induced thrombocytopenia (HIT) complicated by COVID-19

Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia

COVID-19 patients often show high-titer nonplatelet-activating anti-PF4/heparin IgG antibodies

Heparin induced thrombocytopenia in patients with COVID-19

AAV-8 and AAV-9 vectors cooperate with serum proteins differently than AAV-1 and AAV-6

Adenovirusplatelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver

Risk factors for heparin-induced thrombocytopenia: focus on Fcgamma receptors

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination

Pathologic antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 vaccination

Common Terminology Criteria for Adverse Events. Version 5

GPNI. Guidance produced from the Expert Haematology Panel (EHP) focused on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus vaccination

Canadian Covid-19 Science Advisory Table. Thrombosis Canada. Vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)

Groupe Français d'études sur l'Hémostase et la Thrombose (GFHT)

Thrombose Astra Zeneca: essayons de comprendre

Statement from the ISTH on reports indicating blood clots associated with the AstraZeneca vaccine

Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET)

SISET circa le trombosi cerebrali e viscerali con trombocitopenia segnalate in soggetti in precedenza vaccinati con vaccino Vaxzevria (AstraZeneca)

visce rali-con-tromb ocito penia -segna late-in-sogge tti-in-prece denza -vacci nati-con-vacci no-vaxze vria-astra zeneca

Vaccineinduced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors

COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome